Ina Research Inc. (E20922) Balance sheet

Market cap

P/E ratio

Inari Research provides contract testing services to help pharmaceutical companies evaluate drug safety and effectiveness using GLP-compliant laboratory facilities.

Summary Financials Dividends History Workforce

Income statement Balance sheet Cash flow Other

	2012/03	2013/03	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03
Cash and cash equivalents	-	247	407	456	139	234	879	382	464	656	972
Accounts receivable, net	-	302	408	565	489	652	382	-	-	-	-
Inventories	-	3	2	3	1	1	1	1	1	0	0
Total current assets	-	1,410	1,638	1,490	1,116	1,464	2,045	1,855	1,920	2,391	3,168
Property, plant and equipment, net	-	2,307	2,211	2,174	1,466	1,365	1,324	1,330	1,487	1,477	1,457
Total non-current assets	-	2,759	2,622	2,588	1,522	1,408	1,367	1,388	1,547	1,644	1,693
Total assets	-	4,173	4,263	4,080	2,638	2,872	3,412	3,242	3,467	4,035	4,861
Accounts payable	-	260	256	273	309	359	300	-	-	-	-
Short-term debt	-	200	175	575	307	447	497	100	100	100	-
Long-term debt, current	-	309	335	176	101	299	299	100	100	120	120
Total current liabilities	-	1,560	1,590	1,557	1,147	1,582	1,981	1,444	1,640	2,038	2,678
Long-term debt, non-current	-	540	588	493	829	621	621	900	800	765	645
Total non-current liabilities	-	823	786	645	949	730	726	1,037	1,028	965	819
Total liabilities	-	2,382	2,376	2,202	2,096	2,311	2,707	2,480	2,668	3,004	3,498
Common stock and paid-in capital	-	1,286	1,286	1,286	1,286	1,286	1,286	1,286	1,286	1,286	1,031
Retained earnings	-	505	601	591	-744	-726	-581	-524	-487	-255	332
Stockholders' equity	1,803	1,791	1,887	1,877	542	560	705	762	799	1,031	1,364